Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.72 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.64 |
| ▸ | TTR | P02766 | 3/20 | 0.64 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.64 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.64 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.64 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.64 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031824 | 0.93 | PTGS2 (0.76) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| SCHEMBL1032508 | 0.92 | PTGS2 (0.75) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| SCHEMBL6036587 | 0.87 | TTR (0.69) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| SCHEMBL1031733 | 0.84 | PTGS2 (1.00) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| 5-Hydroxy-Diclofenac SCHEMBL2738864 | 0.83 | CAMK2A (1.00) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| SCHEMBL27752715 | 0.83 | PTGS2 (0.55) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| SCHEMBL29398972 | 0.83 | PTGS2 (0.66) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| SCHEMBL1030956 | 0.83 | PTGS2 (0.66) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| SCHEMBL1032030 | 0.82 | PTGS2 (0.56) | PTGS2CAMK2APTGS1TTRCXCL8 | |
| SCHEMBL1032831 | 0.82 | PTGS2 (0.61) | PTGS2CAMK2APTGS1TTRCXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007505-B1 | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES | NOVARTIS AG (CH) | 2003-04-16 | — | — | EP | claimed |
| US-7115662-B2 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS AG (CH) | 2006-10-03 | — | — | US | disclosed |
| US-20040122254-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-6727281-B2 | SELECTIVE CYCLOOXYGENASE-2(COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-04-27 | — | — | US | disclosed |
| US-20020183391-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-12-05 | — | — | US | disclosed |
| US-6451858-B2 | FOR THERAPY OF INFLAMMATION, PYRESIS, PAIN, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, MIGRAINE HEADACHE, CANCER, MELANOMA, MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, OSTEOPOROSIS, ASTHMA, LUPUS AND PSORIASIS; SIDE EFFECT REDUCTION | NOVARTIS AG (CH) | 2002-09-17 | — | — | US | disclosed |
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-01-31 | — | — | US | disclosed |
| US-6310099-B1 | 5-METHYL OR ETHYL-2-(2-'CHLORO OR FLUORO OR TRIFLUROMETHYL-6'FLUORO OR CHLOROANILINO) PHENYLACETIC ACID OR SALT IS USED AS COX-2 SELECTIVE CYCLOOXYGENASE INHIBITOR | NOVARTIS AG (CH) | 2001-10-30 | — | — | US | disclosed |
| US-6291523-B1 | SELECTIVE COX-2 CYCLOOXYGENASE INHIBITORS | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | HCAR2, CYP2F1, CYP2E1 | PTGS2 5/4885CAMK2A 986/4885PTGS1 4/4885 |
| US-20040122254-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | CYP2F1, CYP2E1, PTGER1 | PTGS2 8/4885CAMK2A 2011/4885PTGS1 5/4885 |
| US-20020183391-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | CYP2F1, CYP2E1, PTGER1 | PTGS2 8/4885CAMK2A 2011/4885PTGS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.